Ingalls & Snyder LLC increased its stake in Merck & Co., Inc. (NYSE:MRK) by 5.2% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 355,250 shares of the company’s stock after buying an additional 17,550 shares during the period. Merck & Co., Inc. accounts for about 1.2% of Ingalls & Snyder LLC’s holdings, making the stock its 18th largest holding. Ingalls & Snyder LLC’s holdings in Merck & Co., Inc. were worth $22,747,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in Merck & Co., Inc. by 1.7% during the 2nd quarter. Vanguard Group Inc. now owns 194,144,317 shares of the company’s stock valued at $12,442,709,000 after purchasing an additional 3,312,459 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in Merck & Co., Inc. by 71.5% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 6,281,855 shares of the company’s stock valued at $402,604,000 after purchasing an additional 2,618,435 shares during the last quarter. Principal Financial Group Inc. boosted its stake in Merck & Co., Inc. by 40.4% during the 2nd quarter. Principal Financial Group Inc. now owns 8,012,726 shares of the company’s stock valued at $513,535,000 after purchasing an additional 2,304,142 shares during the last quarter. Canada Pension Plan Investment Board boosted its stake in Merck & Co., Inc. by 70.4% during the 1st quarter. Canada Pension Plan Investment Board now owns 5,568,791 shares of the company’s stock valued at $353,841,000 after purchasing an additional 2,300,200 shares during the last quarter. Finally, Parametric Portfolio Associates LLC boosted its stake in Merck & Co., Inc. by 36.3% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 7,766,906 shares of the company’s stock valued at $497,774,000 after purchasing an additional 2,070,487 shares during the last quarter. Institutional investors own 73.63% of the company’s stock.

In related news, Director Thomas H. Glocer sold 5,000 shares of the firm’s stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total value of $281,000.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.25% of the stock is currently owned by company insiders.

MRK has been the topic of several recent analyst reports. BMO Capital Markets set a $70.00 target price on Merck & Co., Inc. and gave the company a “buy” rating in a research note on Wednesday, October 11th. J P Morgan Chase & Co set a $70.00 price target on Merck & Co., Inc. and gave the company a “buy” rating in a report on Sunday, October 29th. Citigroup raised Merck & Co., Inc. from a “neutral” rating to a “buy” rating and set a $72.00 price target on the stock in a report on Wednesday, October 18th. UBS lowered their price target on Merck & Co., Inc. from $72.00 to $67.00 and set a “buy” rating on the stock in a report on Monday, October 30th. Finally, Sanford C. Bernstein reissued a “buy” rating and set a $64.00 price target on shares of Merck & Co., Inc. in a report on Wednesday, November 15th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the company. Merck & Co., Inc. presently has an average rating of “Hold” and an average price target of $66.29.

Merck & Co., Inc. (NYSE MRK) opened at $56.23 on Wednesday. Merck & Co., Inc. has a twelve month low of $53.63 and a twelve month high of $66.80. The company has a market capitalization of $153,222.34, a price-to-earnings ratio of 14.46, a P/E/G ratio of 2.90 and a beta of 0.76. The company has a quick ratio of 1.16, a current ratio of 1.43 and a debt-to-equity ratio of 0.57.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Friday, October 27th. The company reported $1.11 EPS for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.08. Merck & Co., Inc. had a return on equity of 27.08% and a net margin of 11.60%. The company had revenue of $10.33 billion for the quarter, compared to analysts’ expectations of $10.54 billion. During the same period last year, the firm earned $1.07 EPS. Merck & Co., Inc.’s revenue for the quarter was down 2.0% compared to the same quarter last year. analysts anticipate that Merck & Co., Inc. will post 3.95 earnings per share for the current year.

Merck & Co., Inc. declared that its Board of Directors has approved a share buyback program on Tuesday, November 28th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company’s board believes its shares are undervalued.

The business also recently announced a quarterly dividend, which will be paid on Monday, January 8th. Investors of record on Friday, December 15th will be issued a $0.48 dividend. This is a boost from Merck & Co., Inc.’s previous quarterly dividend of $0.47. This represents a $1.92 dividend on an annualized basis and a yield of 3.41%. The ex-dividend date of this dividend is Thursday, December 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 114.97%.

COPYRIGHT VIOLATION WARNING: This piece was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.watchlistnews.com/ingalls-snyder-llc-buys-17550-shares-of-merck-co-inc-mrk/1774026.html.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.